A5039147214- Prostate Cancer Treatment and Research
- Immunotherapy and Immune Responses
- Radiopharmaceutical Chemistry and Applications
- Cancer Immunotherapy and Biomarkers
- Prostate Cancer Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Cancer, Lipids, and Metabolism
- CAR-T cell therapy research
- Cancer Treatment and Pharmacology
- PARP inhibition in cancer therapy
- Genetic factors in colorectal cancer
- Hormonal and reproductive studies
- Monoclonal and Polyclonal Antibodies Research
- Estrogen and related hormone effects
- Ubiquitin and proteasome pathways
- Heat shock proteins research
- Bone health and treatments
- Glycosylation and Glycoproteins Research
- Cancer, Stress, Anesthesia, and Immune Response
- vaccines and immunoinformatics approaches
- Virus-based gene therapy research
- RNA modifications and cancer
- Immune Cell Function and Interaction
- RNA Interference and Gene Delivery
- Multiple Myeloma Research and Treatments
Memorial Sloan Kettering Cancer Center
2016-2025
Cornell University
2014-2025
Kettering University
1999-2023
Weill Cornell Medicine
2020-2023
John Wiley & Sons (United States)
2015-2021
Sidney Kimmel Comprehensive Cancer Center
2004-2021
Johns Hopkins University
2004-2021
Johns Hopkins Medicine
2019-2021
GTx (United States)
2020
University of Washington
2009-2018
Evolving treatments, disease phenotypes, and biology, together with a changing drug development environment, have created the need to revise castration-resistant prostate cancer (CRPC) clinical trial recommendations succeed those from prior Prostate Cancer Clinical Trials Working Groups.An international expert committee of investigators (the Group 3 [PCWG3]) was reconvened expanded met in 2012-2015 formulate updated criteria on basis emerging data validation studies 2 recommendations.PCWG3...
CTLA-4 blocking antibody induces secondary hypophysitis by binding to antigen and initiating a type II hypersensitivity reaction.
The anti-programmed cell death protein 1 (PD-1) antibody pembrolizumab is approved by the US Food and Drug Administration for treatment of microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) solid tumors, but prevalence MSI-H/dMMR prostate cancer clinical utility immune checkpoint blockade in this disease subset are unknown.To define benefit anti-PD-1/programmed ligand (PD-L1) therapy molecularly defined population.In case series, 1551 tumors from 1346 patients with...
Purpose A long natural history and a predominant osseous pattern of metastatic spread are impediments to the adoption precision medicine in patients with prostate cancer. To establish feasibility clinical genomic profiling this disease, we performed targeted deep sequencing tumor normal DNA from locoregional, noncastrate, castration-resistant Patients Methods consented analysis their germline DNA. hybridization capture-based assay was used identify single-nucleotide variations, small...
Abstract Answer questions and earn CME/CNE Prostate cancer survivors approach 2.8 million in number represent 1 5 of all the United States. While guidelines exist for timely treatment surveillance recurrent disease, there is limited availability that facilitate provision posttreatment clinical follow‐up care to address myriad long‐term late effects may face. Based on recommendations set forth by a National Cancer Survivorship Resource Center expert panel, American Society developed primary...
Purpose ARN-509 is a novel androgen receptor (AR) antagonist for the treatment of castration-resistant prostate cancer (CRPC). inhibits AR nuclear translocation and binding to response elements and, unlike bicalutamide, does not exhibit agonist properties in context overexpression. This first-in-human phase I study assessed safety, tolerability, pharmacokinetics, pharmacodynamics, antitumor activity men with metastatic CRPC. Patients Methods Thirty patients progressive CRPC received...
The relative cardiovascular safety of gonadotropin-releasing hormone (GnRH) antagonists compared with GnRH agonists in men prostate cancer and known atherosclerotic disease remains controversial.In this international, multicenter, prospective, randomized, open-label trial, concomitant were randomly assigned 1:1 to receive the antagonist degarelix or agonist leuprolide for 12 months. primary outcome was time first adjudicated major adverse event (composite death, myocardial infarction,...
The complex carbohydrate molecule globo H hexasaccharide has been synthesized, conjugated to keyhole limpet hemocyanin, and administered with the immunologic adjuvant QS-21 as a vaccine for patients prostate cancer who have relapsed after primary therapies such radiation or surgery. Globo is one of several candidate antigens present on cells that can serve targets immune recognition treatment strategies. vaccine, given five subcutaneous vaccinations over 26 weeks, shown be safe capable...
Abstract Purpose: To define the maximum tolerated dose (MTD), toxicities, and pharmacokinetics of 17-allylamino-17-demethoxygeldanamycin (17-AAG) when administered using continuous intermittent dosing schedules. Experimental Design: Patients with progressive solid tumor malignancies were treated 17-AAG an accelerated titration escalation schema. The starting schedule 5 mg/m2 daily for days cycles repeated every 21 days. Dosing modifications based on safety, pharmacodynamic modeling, clinical...
To define methodology to show clinical benefit for patients in the state of a rising prostate-specific antigen (PSA).A states framework was used address hypothesis that definitive phase III trials could not be conducted this patient population.The Group focused on men with systemic (nonlocalized) recurrence and defined risk developing clinically detectable metastases. Models versus local recurrence, metastatic progression were discussed.Therapies have shown favorable effects more advanced...
Alterations in DNA damage repair (DDR) genes occur up to 25% of patients with metastatic castration-resistant prostate cancer (mCRPC) and may sensitize platinum chemotherapy. We aimed evaluate the efficacy platinum-based chemotherapy DDR-mutant (DDRmut) mCRPC.We assessed response based on DDR gene alteration status men mCRPC who underwent tumor germline genomic profiling. Patients deleterious alterations a panel that included BRCA2, BRCA1, ATM, PALB2, FANCA, CDK12 were considered DDRmut.A...
Androgen deprivation therapy is the cornerstone of treatment for patients with advanced prostate cancer. Meta-analysis small, oncology-focused trials suggest gonadotropin-releasing hormone (GnRH) antagonists may be associated fewer adverse cardiovascular outcomes compared GnRH agonists.
PURPOSE: To determine the safety and activity of weekly paclitaxel in combination with estramustine carboplatin (TEC) patients advanced prostate cancer. PATIENTS AND METHODS: In a dose-escalation study, cancer were administered (weekly 1-hour infusions 60 to 100 mg/m 2 ), oral (10 mg/kg), (area under curve, 6 mg/mL-min every 4 weeks). Paclitaxel levels determined 0, 30, 60, 90, 120 minutes 18 hours after infusion, concentration-time curve was estimated. Once safe dose established,...
Purpose: We report the synthesis of a mucin-related O-linked glycopeptide, α-N-acetylgalactosamine-O-serine/threonine (Tn), which is highly simplistic in its structure and can induce relevant humoral response when given trimer or clustered (c) formation. tested for an antitumor effect, form change posttreatment versus pretreatment prostate-specific antigen (PSA) slopes, that might serve as surrogate effectiveness vaccines delaying time to radiographic progression. Methods: compared antibody...
MLN2704 is an immunoconjugate designed to deliver the maytansinoid antimicrotubule agent drug maytansinoid-1 directly prostate-specific membrane antigen (PSMA)-expressing cells via PSMA-targeted monoclonal antibody MLN591. This novel has shown cytotoxic anti-prostate cancer activity. study investigated safety profile, pharmacokinetics, immunogenicity, and preliminary antitumor activity of MLN2704.Patients with progressive, metastatic, castration-resistant prostate received intravenously over...
Abstract BACKGROUND The clinical effects of targeting HER‐2 in prostate carcinoma are not known. This study explored the feasibility molecular profiling to determine correlation between expression, hormonal sensitivity, and antitumor trastuzumab paclitaxel patients with carcinoma. METHODS Patients progressive androgen dependent (AD) independent (AI) were eligible participate study. expression was assessed on pretreatment tissue specimens, then assigned one four treatment groups: AD positive,...